Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement

BMC Immunol. 2020 Jun 29;21(1):39. doi: 10.1186/s12865-020-00368-7.

Abstract

Background: The effects of intravenous immunoglobulin G replacement on perceived health and infection susceptibility of patients suffering from immunoglobulin G (IgG) deficiencies should be evaluated in a prospective analysis.

Methods: Patients with symptomatic primary or secondary IgG deficiencies were interviewed prior to the first IgG infusion (t0) and over the course of their treatment (t1 - t6). The respondents rated their current health using a 100 point scale (EQ-5D-5L), ranging from 0 ('worst imaginable health') to 100 ('best imaginable health'). The patients also provided information on the frequency of infections and of infections requiring antibiotics in the past 8 weeks. A healthy control group (CG) without oncologic diseases answered the questions once.

Results: One hundred six patients with a median age of 65 years (21-85 years) were investigated. The median serum IgG concentration changed from 500 mg/dl (t0) to 772 mg/dl (t6). The mean number of infections and of infections requiring antibiotics decreased during IgG replacement significantly. Current health according to EQ-5D-5L improved from 57 (t0) to 68 (t6), compared to 73 in the CG.

Conclusion: During the course of IgG replacement patients reported fewer and less severe infections. Their health assessment improved but still was inferior to the healthy CG.

Keywords: IgG replacement; Immunoglobulin G deficiencies; Infections; Outpatient treatment; Perceived health.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Health Status
  • Humans
  • IgG Deficiency / epidemiology
  • IgG Deficiency / therapy*
  • Immunoglobulins, Intravenous / therapeutic use*
  • Infections / epidemiology*
  • Male
  • Middle Aged
  • Perception
  • Prospective Studies
  • Severity of Illness Index
  • Young Adult

Substances

  • Immunoglobulins, Intravenous